NEW YORK, March 27, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,500,000 shares of common stock of the Company originally issued in January 2023, having an exercise price of $5.00 per share, at a reduced exercise price of $1.6775 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-3 (No. 333-269224). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $4.2 million, prior to deducting placement agent fees and estimated offering expenses.
NEW YORK, Feb. 26, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has completed bioanalytical method development under its prior agreement with Altasciences and plans to further engage Altasciences to perform a key study of mouse blood and plasma analysis from samples collected in Hoth's sponsored scientific research conducted at NC State University. The blood and plasma samples collected are part of a dose response study in a humanized mouse model. The upcoming study will use the newly validated bioanalytical method developed at Altasciences to test the amount of HT-KIT from the dose response study and help determine how long HT-KIT remains in the blood stream post dosing.
NEW YORK, Feb. 13, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to attend the BIO CEO and Investor Conference in New York, NY.
NEW YORK, Jan. 18, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has received U.S. Food and Drug Administration (FDA) clearance to implement a number of protocol amendments to its ongoing clinical trial for HT-001, which is being developed as a potential treatment for cancer patients undergoing treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRI). The trial is being conducted under Hoth's open Investigational New Drug Application (IND) for HT-001.
NEW YORK, Dec. 27, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has received approval from the University of Miami to enroll patients for its first in human clinical trial of HT-001.
NEW YORK, Dec. 5, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has completed the manufacturing of its drug substance HT-KIT using good laboratory practice (GLP). HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frame shifting and already has Orphan Drug Designation from the U.S. Food and Drug Administration (FDA). Hoth also recently completed its Pre-IND meeting with FDA in November.
NEW YORK, Nov. 14, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today the successful completion of a pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding the Company's development plan for its HT-KIT therapeutic. The Pre-IND meeting was completed through written responses provided by the FDA Nonmalignant Hematology Division of Regulatory Operations for Cardiology, Hematology, Endocrinology, and Nephrology.
Hoth to Present at NobleCon's 19th Annual Emerging Growth Investor Conference
NEW YORK, Oct. 5, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced, its initiative to utilize Artificial Intelligence to both screen its current pipeline as well as utilize AI for licensing opportunities in acquiring or partnering novel therapeutics for rare diseases.
NEW YORK, Oct. 2, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the Pre-IND meeting requested on September 8th for HT-KIT with the U.S. Food and Drug Administration (FDA) has been granted to receive written responses only from the FDA that are targeted for delivery on November 7, 2023.